Last reviewed · How we verify
Group Hydroxychloroquine and apixaban
This combination pairs hydroxychloroquine, an immunomodulator that reduces inflammation and autoimmune activity, with apixaban, an anticoagulant that inhibits Factor Xa to prevent thrombosis.
This combination pairs hydroxychloroquine, an immunomodulator that reduces inflammation and autoimmune activity, with apixaban, an anticoagulant that inhibits Factor Xa to prevent thrombosis. Used for Likely autoimmune or inflammatory condition with thrombotic risk (specific indication not publicly detailed for this Phase 3 trial).
At a glance
| Generic name | Group Hydroxychloroquine and apixaban |
|---|---|
| Also known as | Hydroxychloroquine, Apixaban and standard treatment |
| Sponsor | Universidade do Vale do Sapucai |
| Drug class | Combination therapy: antimalarial immunomodulator + anticoagulant |
| Target | Hydroxychloroquine: lysosomal pH and immune signaling; Apixaban: Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine works by accumulating in lysosomes, reducing inflammatory cytokine production and modulating immune responses, making it useful in autoimmune and inflammatory conditions. Apixaban is a direct Factor Xa inhibitor that prevents thrombin generation and clot formation. Together, this combination may address both inflammatory/autoimmune pathology and associated thrombotic risk.
Approved indications
- Likely autoimmune or inflammatory condition with thrombotic risk (specific indication not publicly detailed for this Phase 3 trial)
Common side effects
- Bleeding (apixaban-related)
- Gastrointestinal disturbance
- Retinopathy (hydroxychloroquine-related, long-term)
- Myalgia or arthralgia
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Prevention of Complications (SARS-CoV-2): Clinical Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: